These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29674328)

  • 41. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
    Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ
    J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of Treprostinil in Pediatric Pulmonary Hypertension: Case Reports and Review of the Literature.
    Gavotto A; Thomas F; Werner O; Moreau J; Amedro P
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):23-31. PubMed ID: 32168152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year experience at a single center.
    Levine M; Curry SC; Padilla-Jones A; Ruha AM
    Ann Emerg Med; 2013 Sep; 62(3):252-8. PubMed ID: 23642908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T; Seeger W; Schmehl T
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum: A Retrospective Observational Case Series Study.
    Wang T; Lu J; Li Q; Chen Y; Ye Q; Gao J; Yang D; Zhao L; Huang J; Zhang J
    Anesth Analg; 2019 Dec; 129(6):1607-1612. PubMed ID: 31743181
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
    Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
    Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension.
    Skoro-Sajer N; Lang IM; Harja E; Kneussl MP; Sing WG; Gibbs SJ
    Clin Pharmacokinet; 2008; 47(9):611-8. PubMed ID: 18698881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension.
    Skoro-Sajer N; Gerges C; Balint OH; Kohalmi D; Kaldararova M; Simkova I; Jakowitsch J; Gabriel H; Baumgartner H; Gerges M; Sadushi-Kolici R; Celermajer DS; Lang IM
    Heart; 2018 Jul; 104(14):1195-1199. PubMed ID: 29436381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension.
    Mouratoglou SA; Patsiala A; Feloukidis C; Karvounis H; Giannakoulas G
    Int J Cardiol; 2020 May; 306():187-189. PubMed ID: 32115272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil.
    López-Medrano F; Fernández-Ruiz M; Ruiz-Cano MJ; Barrios E; Vicente-Hernández M; Aguado JM; Escribano P
    Arch Bronconeumol; 2012 Dec; 48(12):443-7. PubMed ID: 22858303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A pediatric case study of treprostinil overdose.
    Walsh M; Hanna BD
    J Heart Lung Transplant; 2009 Mar; 28(3):297-8. PubMed ID: 19285625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and tolerability of subcutaneous treprostinil in newborns with congenital diaphragmatic hernia and life-threatening pulmonary hypertension.
    Carpentier E; Mur S; Aubry E; Pognon L; Rakza T; Flamein F; Sharma D; Tourneux P; Storme L
    J Pediatr Surg; 2017 Sep; 52(9):1480-1483. PubMed ID: 28389079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
    Lang I; Gomez-Sanchez M; Kneussl M; Naeije R; Escribano P; Skoro-Sajer N; Vachiery JL
    Chest; 2006 Jun; 129(6):1636-43. PubMed ID: 16778286
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
    Barst RJ; Galie N; Naeije R; Simonneau G; Jeffs R; Arneson C; Rubin LJ
    Eur Respir J; 2006 Dec; 28(6):1195-203. PubMed ID: 16899485
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
    Furukawa A; Tamura Y; Iwahori H; Goto M; Ohashi N; Okabe T; Kawamura A
    BMC Pulm Med; 2017 Oct; 17(1):135. PubMed ID: 29073911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension.
    Voswinckel R; Reichenberger F; Gall H; Schmehl T; Gessler T; Schermuly RT; Grimminger F; Rubin LJ; Seeger W; Ghofrani HA; Olschewski H
    Pulm Pharmacol Ther; 2009 Feb; 22(1):50-6. PubMed ID: 19071225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.